my personal edition > diabetes > news
E-Mail this DGNews to a colleague
DGNews
Byetta (Exenatide) and Postmarketing Reports of Acute Pancreatitis
BETHESDA, MD -- October 16, 2007 -- U.S. Food and Drug Administration (FDA) has reviewed 30 postmarketing reports of acute pancreatitis in patients taking Byetta (exenatide), a drug used to treat adults with type 2 diabetes.
An association between Byetta and acute pancreatitis is suspected in some of these cases. Amylin Pharmaceuticals, Inc. has agreed to include information about acute pancreatitis in the "Precautions" section of the product label.
Healthcare professionals should be alert to the signs and symptoms of acute pancreatitis and instruct patients taking Byetta to seek prompt medical care if they experience unexplained, persistent, severe abdominal pain which may or may not be accompanied by vomiting. If pancreatitis is suspected, Byetta should be discontinued. If pancreatitis is confirmed, Byetta should not be restarted unless an alternative etiology is identified.
SOURCE: U.S. Food and Drug Administration
All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.
| 
